'Liposuction leftovers' easily converted to iPS cells, study shows
Joseph Wu, Ning Sun and Michael Longaker collaborated on research that showed stem cells found in fat tissue could easily be converted into iPS cells.
Globs of human fat removed during liposuction conceal versatile cells that are more quickly and easily coaxed to become induced pluripotent stem cells, or iPS cells, than are the skin cells most often used by researchers, according to a new study from Stanford’s School of Medicine.
“We’ve identified a great natural resource,” said Stanford surgery professor and co-author of the research, Michael Longaker, MD, who has called the readily available liposuction leftovers “liquid gold.” Reprogramming adult cells to function like embryonic stem cells is one way researchers hope to create patient-specific cell lines to regenerate tissue or to study specific diseases in the laboratory.
“Thirty to 40 percent of adults in this country are obese,” agreed cardiologist Joseph Wu, MD, PhD, the paper’s senior author. “Not only can we start with a lot of cells, we can reprogram them much more efficiently. Fibroblasts, or skin cells, must be grown in the lab for three weeks or more before they can be reprogrammed. But these stem cells from fat are ready to go right away.”
The fact that the cells can also be converted without the need for mouse-derived “feeder cells” may make them an ideal starting material for human therapies. Feeder cells are often used when growing human skin cells outside the body, but physicians worry that cross-species contamination could make them unsuitable for human use.
The findings will be published online Sept. 7 in the Proceedings of the National Academy of Sciences. Longaker is the deputy director of Stanford’s Stem Cell Biology and Regenerative Medicine Institute and director of children’s surgical research at Lucile Packard Children’s Hospital. Wu is an assistant professor of cardiology and radiology, and a member of Stanford’s Cardiovascular Institute.
Even those of us who are not obese would probably be happy to part with a couple of pounds (or more) of flab. Nestled within this unwanted latticework of fat cells and collagen are multipotent cells called adipose, or fat, stem cells. Unlike highly specialized skin-cell fibroblasts, these cells in the fat have a relatively wide portfolio of differentiation options—becoming fat, bone or muscle as needed. It’s this pre-existing flexibility, the researchers believe, that gives these cell an edge over the skin cells.
“These cells are not as far along on the differentiation pathway, so they’re easier to back up to an earlier state,” said first author and postdoctoral scholar Ning Sun, PhD, who conducted the research in both Longaker’s and Wu’s laboratories. “They are more embryonic-like than fibroblasts, which take more effort to reprogram.”
These reprogrammed iPS cells are usually created by expressing four genes, called Yamanaka factors, normally unexpressed (or expressed at very low levels) in adult cells.
Sun found that the fat stem cells actually express higher starting levels of two of the four reprogramming genes than do adult skin cells—suggesting that these cells are already primed for change. When he added all four genes, about 0.01 percent of the skin-cell fibroblasts eventually became iPS cells but about 0.2 percent of the fat stem cells did so—a 20-fold improvement in efficiency.
The new iPS cells passed the standard tests for pluripotency: They formed tumors called teratomas when injected into immunocompromised mice, and they could differentiate into cells from the three main tissue types in the body, including neurons, muscle and gut epithelium. The researchers are now investigating whether the gene expression profiles of the fat stem cells could be used to identify a subpopulation that could be reprogrammed even more efficiently.
“The idea of reprogramming a cell from your body to become anything your body needs is very exciting,” said Longaker, who emphasized that the work involved not just a collaboration between his lab and Wu’s, but also between the two Stanford institutes. “The field now needs to move forward in ways that the Food and Drug Administration would approve —with cells that can be efficiently reprogrammed without the risk of cross-species contamination—and Stanford is an ideal place for that to happen.”
“Imagine if we could isolate fat cells from a patient with some type of congenital cardiac disease,” said Wu. “We could then differentiate them into cardiac cells, study how they respond to different drugs or stimuli and see how they compare to normal cells. This would be a great advance.”
In addition to Sun, Wu and Longaker, other Stanford collaborators on the research include postdoctoral scholars Nicholas Panetta, MD, Deepak Gupta, MD, and Shijun Hu, PhD; graduate student Kitchener Wilson; medical student Andrew Lee; research assistant Fangjun Jia, PhD; associate professor of pathology and of pediatrics Athena Cherry, PhD; and professor of cardiothoracic surgery Robert Robbins, MD.
The research was supported by the Mallinckrodt Foundation, the American Heart Association, the California Institute for Regenerative Medicine, the National Institutes of Health, the Stanford Cardiovascular Institute, the Oak Foundation and the Hagey Laboratory for Pediatric Regenerative Medicine.
Stanford Medicine integrates research, medical education and health care at its three institutions - Stanford University School of Medicine, Stanford Health Care (formerly Stanford Hospital & Clinics), and Lucile Packard Children's Hospital Stanford. For more information, please visit the Office of Communication & Public Affairs site at http://mednews.stanford.edu.